Cooper Companies (NASDAQ:COO) Releases Earnings Results, Beats Expectations By $0.03 EPS

Cooper Companies (NASDAQ:COO) posted its quarterly earnings results on Wednesday. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03, Zacks reports. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies updated its Q4 2026 guidance to 1.050-1.090 EPS and its FY 2026 guidance to 4.510-4.550 EPS.

Cooper Companies Stock Down 6.2%

COO traded down $4.21 during trading on Wednesday, hitting $63.48. 8,920,917 shares of the company’s stock traded hands, compared to its average volume of 2,349,299. The stock has a market capitalization of $12.38 billion, a price-to-earnings ratio of 53.80, a PEG ratio of 1.82 and a beta of 0.82. The company has a current ratio of 1.27, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23. Cooper Companies has a 12-month low of $58.89 and a 12-month high of $89.83. The company’s 50 day simple moving average is $72.59 and its two-hundred day simple moving average is $70.17.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Robert W. Baird cut their target price on shares of Cooper Companies from $98.00 to $85.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Citigroup restated a “neutral” rating and issued a $80.00 target price (up from $76.00) on shares of Cooper Companies in a research report on Thursday, August 13th. JPMorgan Chase & Co. decreased their target price on shares of Cooper Companies from $80.00 to $71.00 and set a “neutral” rating on the stock in a research report on Friday, June 5th. Stifel Nicolaus reduced their price target on Cooper Companies from $95.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, June 5th. Finally, UBS Group started coverage on Cooper Companies in a research note on Tuesday, July 28th. They set a “neutral” rating and a $75.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Cooper Companies has an average rating of “Hold” and a consensus price target of $81.64.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies increased its share-repurchase authorization from $2 billion to $3 billion. The larger buyback could support earnings per share and signal that management views the stock as undervalued. The company also said its board remains open to other value-creation options. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: CooperCompanies completed its strategic review and unanimously decided to retain CooperSurgical. While the decision removes uncertainty around the business, it also means the company will not receive a potential near-term cash infusion from a sale or separation. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: The company released fiscal third-quarter 2026 results for the period ended July 31. The supplied announcement does not include the reported revenue or earnings figures, so the market’s reaction is likely being driven primarily by the forward guidance. CooperCompanies Announces Third Quarter 2026 Results
• Negative Sentiment: Fiscal 2026 adjusted EPS guidance of $4.51–$4.55 is below the consensus estimate of $4.63. Revenue guidance of $4.2–$4.3 billion is also below or only reaches the $4.3 billion consensus at the high end, suggesting weaker-than-expected growth or profitability.
• Negative Sentiment: Fourth-quarter 2026 EPS guidance of $1.05–$1.09 is well below the $1.20 consensus estimate. Although revenue guidance of approximately $1.1 billion is broadly in line with expectations, the earnings shortfall indicates pressure on margins, costs, or the business mix.

Institutional Investors Weigh In On Cooper Companies

Several institutional investors and hedge funds have recently added to or reduced their stakes in COO. CYBER HORNET ETFs LLC bought a new stake in shares of Cooper Companies during the 2nd quarter valued at about $36,000. MUFG Securities EMEA plc purchased a new stake in Cooper Companies in the 2nd quarter worth approximately $42,000. IFP Advisors Inc raised its stake in Cooper Companies by 2,647.8% during the 3rd quarter. IFP Advisors Inc now owns 632 shares of the medical device company’s stock worth $43,000 after acquiring an additional 609 shares during the period. Johnson Financial Group Inc. purchased a new position in Cooper Companies during the third quarter valued at approximately $59,000. Finally, Quarry LP bought a new position in shares of Cooper Companies in the fourth quarter worth approximately $70,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.